A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.

bamlanivimab (LY-CoV555) - Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/36775970

Feb 14, 2023